Co-Existent Endometrial and Ovarian Carcinoma: Molecular Stratification for Pathologic Reporting and Clinical Management
Key facts
- Who runs it
- British Columbia Cancer Agency
- Where
- Canada1 site in 1 countryChoose a country to see its sites
- Trial code
- Status
- Not yet recruiting
- Phase
- Phase 2
- People taking part
- 90 people, planned
- Started
- 30 Oct 2026
- Expected to end
- 30 Oct 2032
- Type of study
- Interventional, 2 groups
- Treatments tested
- Treatment De-escalation
- Additional Treatment
- Record updated
- 16 November 2026
Who can take part
- Age
- 18 years and older
- Sex
- Women only
- Healthy volunteers
- Cannot take part
Show the full registry criteria (9)Hide the full registry criteria
Who can take part
- Had primary surgery consisting of hysterectomy (any surgical approach) and bilateral salpingo-oophorectomy
- Lymph node dissection can be performed as per institutional practice (sentinel node biopsy or full)
- Had no macroscopic residual disease after surgery; Meet the molecular and pathological criteria (1, 2, or 3) as determined or identified by their local oncologist and pathologist:
- (Molecular) NSMP ER strong positive:; Endometrial site; Low grade endometrioid (grade 1-2); <50% myometrial invasion (FIGO 2009 stage IA); Absence of substantial lymphovascular invasion (LVI); Ovarian site; Low grade endometrioid (grade 1-2); bilateral (stage IB),; intraoperative spill (stage ICI),; preoperative rupture (stage IC2),; surface involvement (stage IC2)
- (Molecular) POLEmut; Endometrial site; FIGO 2009 stage IA or IB (regardless of grade, histotype, myoinvasion or LVI); Ovarian site; Low grade endometrioid (grade 1-2); bilateral (stage IB),; intraoperative spill (stage ICI),; preoperative rupture (stage IC2),; surface involvement (stage IC2),
- (Molecular) MSH2, MSH6, or PMS2 loss (MMRd without MLH1 promoter hypermethylation); Endometrial site; FIGO 2009 stage IA or IB (regardless of grade, histotype, myoinvasion or LVI); Ovarian site; Low grade endometrioid (grade 1-2); bilateral (stage IB),; intraoperative spill (stage ICI),; preoperative rupture (stage IC2),; surface involvement (stage IC2),
Who cannot take part
- Individuals with MMRd MLH1 promoter hypermethylation or p53abn status in their ovarian or endometrial tumour
- Individuals with ER negative-low status in the endometrium
- Individuals with any additional sites of metastases
Eligibility questionnaire
From the criteria published for this trial, to help you prepare for a talk with your doctor or the study team. We do not tell you a result. Only the study team can say whether you can take part.
- Age
- Sex
- Ovarian carcinoma or endometrial carcinoma
Where is this trial?
It has sites in one country. Choose a country to see its sites.
About the trial
What the trial wants to find out
Patients with co-existent endometrial and ovarian carcinomas (CEOCs) are treated inconsistently due to a lack of clear standardized treatment guidelines. Patients may be over-treated and face substantial physical side effects and financial challenges due to additional chemotherapy or radiation appointments. Previous retrospective research has shown that using specific molecular and pathologic criteria to stratify patients' CEOC tumours can identify patients at very low risk of cancer recurrence (during an average 6 years of follow-up), with no demonstrated benefit of additional treatment after surgery.
Read full original descriptionShow less
The goal of this study is to determine the safety of receiving no additional treatment (i.e. no chemotherapy or radiation) after surgery in patients diagnosed with a co-existent endometrial and ovarian cancer (CEOC) meeting highly selective molecular and pathologic criteria. Patients with CEOC who also meet predefined molecular criteria (low risk POLEmut, ER+NSMP, or MSH2/MSH6/PMS2 loss without MLH1 promoter hypermethylation in the endometrium and ovary) and pathology criteria (see schema) are eligible to participate. Patients may choose, or be directed by their physician to receive no additional treatment after surgery or to receive additional treatment.
To determine the safety of this approach, the study team will evaluate pelvic recurrence (primary) rate, as well as vaginal and distant recurrences, recurrence-free and disease- specific, and overall survival, quality of life, and health economic metrics among patients who do, and do not receive additional treatment after surgery.
Study design is pragmatic, designed to match recommended standard of care as closely as possible. Patients will have regular follow-up appointments with their oncologist every 4 months for 3 years as part of their medical care. During this time, patients will complete quality of life surveys at baseline, 4, 12, 24, and 36 months. Baseline imaging, and imaging at completion of 3-years are required.
The 2 groups in the trial
- Treatment De-escalationTreatment being tested
After undergoing surgery, patients elect to not receive any further treatment (such as radiation or chemotherapy) to treat their cancer. Instead their condition will be closely followed by their oncologist for 3 years.
- Additional TreatmentOther group
After undergoing surgery, patients elect to receive additional treatment (such as radiation or chemotherapy) to treat their cancer. The type of additional treatment received will be determined by the patient's oncologists in conjunction with the patient. These patients will be closely followed by their oncologist for 3 years.
Next steps
For your doctor
Doctor ask sheet
A PDF for your doctor: what this trial tests, who can take part, and 3 eligibility questions with room for answers and notes.
PDF, US Letter, 1 to 2 pages. A4 size
For the study team
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- Co-Existent Endometrial and Ovarian Carcinoma: Optimization of Treatment Through Molecular and Pathological Refinement
- Criteria questions
- Built from NCT07940062, who can take part
- Record updated
- 16 November 2026